BeyondSpring (BYSI) Income from Non-Controlling Interests (2016 - 2026)
BeyondSpring (BYSI) posted Income from Non-Controlling Interests of -$4.4 million for Q1 2026, down 24.48% sequentially from -$3.5 million in Q4 2025, and down 35.61% YoY from -$6.8 million in Q1 2025.
BeyondSpring (BYSI) Income from Non-Controlling Interests (2016 - 2026) Analysis & Trends
BeyondSpring has reported Income from Non-Controlling Interests for 9 years, with the latest figure at -$4.4 million in Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 35.61% year-over-year to -$4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.1 million (down 66.67% YoY) and the FY2025 annual result came in at -$13.0 million, down 150.27% from the prior year.
- Income from Non-Controlling Interests eased to -$4.4 million in Q1 2026 per BYSI's latest filing, from -$3.5 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at -$57000.0 in Q1 2024 and troughed at -$4.4 million in Q1 2026.
- A 3-year average of -$2.5 million and a median of -$2.8 million in 2024 frame the typical range for Income from Non-Controlling Interests.
- The widest YoY moves for Income from Non-Controlling Interests: up 24.68% in 2025, down 5570.18% in 2025.
- Over 3 years, Income from Non-Controlling Interests stood at -$2.8 million in 2024, then dropped by 24.68% to -$3.5 million in 2025, then retreated by 24.48% to -$4.4 million in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$4.4 million, -$3.5 million, and -$3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | -4.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.01 Mn |
| Mar 31, 2026 | -4.38 Mn |
| Dec 31, 2025 | -3.52 Mn |
| Sep 30, 2025 | -3.45 Mn |
| Jun 30, 2025 | -2.77 Mn |
| Mar 31, 2025 | -3.23 Mn |
| Dec 31, 2024 | -2.82 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Jun 30, 2024 | -58,000.00 |
| Mar 31, 2024 | -57,000.00 |
| Dec 31, 2021 | 2.83 Mn |
| Sep 30, 2021 | -1.78 Mn |
| Jun 30, 2021 | -615,000.00 |
| Mar 31, 2021 | -455,000.00 |
| Dec 31, 2020 | -834,000.00 |
| Sep 30, 2020 | -677,000.00 |
| Jun 30, 2020 | -848,000.00 |
| Mar 31, 2020 | -582,000.00 |
| Dec 31, 2019 | -952,000.00 |
| Sep 30, 2019 | -494,000.00 |